Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study
Ben Van Calster(University Medical Center Utrecht), D. Timmerman(Rega Institute for Medical Research), S. Guerriero(University of Cagliari), A. C. Testa(Università Cattolica del Sacro Cuore), E. Epstein(Karolinska Institutet), D. Fischerová(Charles University), T. Bourne(Luigi Sacco Hospital), L. Savelli(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Juan Luis Alcázar(Universidad de Navarra), Marek Kudła(Medical University of Silesia), L. Valentin(Malmö University), Ignace Vergote(KU Leuven), P. Sladkevicius(Lund University), Robert Fruscio(Azienda Ospedaliera San Gerardo), C. Landolfo(Queen Charlotte's and Chelsea Hospital), L. Jokubkiene(Lund University), An Coosemans(KU Leuven), Laure Wynants(Maastricht University), Nandita Deo(Whipps Cross University Hospital), D. Franchi(European Institute of Oncology), Artur Czekierdowski(Medical University of Lublin), J. Kaijser(KU Leuven), F. Buonomo(IRCCS Materno Infantile Burlo Garofolo), Valentina Chiappa(Fondazione IRCCS Istituto Nazionale dei Tumori), Jolien Ceusters(KU Leuven), Wouter Froyman(Rega Institute for Medical Research), Maria Elisabetta Coccia(University of Florence), F. Leone(University of Milan), Caroline Van Holsbeke(Ziekenhuis Oost-Limburg), Ekaterini Domali(National and Kapodistrian University of Athens)
Cited by 124
Related Papers
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.2k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study
|Journal of Clinical Oncology|2000|840
A calibration hierarchy for risk models was defined: from utopia to empirical data
|Journal of Clinical Epidemiology|2016|834